+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Effect of an opiate antagonist (naloxone) and an agonist/antagonist (nalbuphine) in primate hemorrhagic shock: relationship to catecholamine release



Effect of an opiate antagonist (naloxone) and an agonist/antagonist (nalbuphine) in primate hemorrhagic shock: relationship to catecholamine release



Circulatory Shock 17(4): 313-325



Recent evidence has suggested a relationship between the endogenous opioid peptides and the pathophysiology of various shock states. In the present study, we investigated the relationship between the effectiveness of naloxone (an opiate antagonist) and nalbuphine (an opiate agonist/antagonist), and the changes in circulating levels of catecholamines in the nonhuman primate subjected to hemorrhagic shock. Plasma levels of catecholamines were measured using high-performance liquid chromatography (HPLC) during hemorrhagic shock in 15 female baboons. Plasma levels of both epinephrine and norepinephrine increased significantly during hemorrhagic shock (p less than 0.05), which correlated with an increase in heart rate. Bolus administration of naloxone (5 mg/kg) significantly increased both plasma epinephrine (p less than 0.01) and norepinephrine (p less than 0.05) over shock levels along with a transient but significant increase in cardiac output (p less than 0.05) and mean arterial pressure (p less than 0.05), and a significant decrease in heart rate (p less than 0.05). Improvements in hemodynamics were maintained with a constant infusion of naloxone (5 mg/kg/hr), which also caused a further significant increase in plasma epinephrine (p less than 0.01). Administration of a single bolus of the opiate agonist/antagonist nalbuphine (5 mg/kg) dramatically decreased cardiac output and mean arterial pressure and had no effect on circulating catecholamines. Our results suggest that (1) the beneficial action of high-dose naloxone in primate hemorrhagic shock may be attributable in part to a drug-induced increase in circulating endogenous catecholamines; and (2) the failure of high-dose nalbuphine to improve cardiovascular function may be related to its partial agonist (cardiodepressant) properties at higher doses.

(PDF emailed within 1 workday: $29.90)

Accession: 042894510

Download citation: RISBibTeXText

PMID: 4092345



Related references

Using the opioid antagonist naloxone and the agonist antagonist nalbuphine to eliminate the depressive effect of fentanyl during awakening. Vestnik Akademii Meditsinskikh Nauk SSSR (7): 13-17, 1991

Use of an opioid antagonist naloxone and the agonist-antagonist nalbuphine during the awakening period to eliminate depressive effects of fentanyl. Vestnik Akademii Meditsinskikh Nauk SSSR: 13-17, 1991

Beneficial effect of a new opiate antagonist in hemorrhagic shock. Federation Proceedings: Abstract 7809, 1982

Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone. Journal of Pharmacology and Experimental Therapeutics 251(2): 469-476, 1989

Pharmacological actions of a novel mixed agonist antagonist opiate the benzoylhydrazido derivative of naloxone. Society for Neuroscience Abstracts 14(1): 32, 1988

Opiate agonist antagonist activity of 6 spirohydantoin derivatives of oxymorphone oxycodone naloxone and naltrexone. Federation Proceedings 46(6): 2035, 1987

The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 64(3): 535-543, 1996

Beneficial action of a new opiate antagonist (Win 44,441-3) in hemorrhagic shock. European Journal of Pharmacology 78(3): 307-313, 1982

Manganese as agonist and antagonist of calcium ions dual effect upon catecholamine release from adrenal medulla. Life Sciences 28(13): 1535-1540, 1981

Attenuation of heat shock-induced delayed cardioprotection by the opiate receptor antagonist, naloxone. Journal of Molecular & Cellular Cardiology 33(6): A90, June, 2001

Attenuation of heat shock-induced cardioprotection by treatment with the opiate receptor antagonist naloxone. American Journal of Physiology. Heart and Circulatory Physiology 282(6): H2011-7, 2002

Effect of specific opioid-receptor antagonist naloxone on rats with hereditary hypothalamic diabetes insipidus (Brattleboro strain) during acute hemorrhagic shock. Acta Physiologica et Pharmacologica Bulgarica 12(1): 62-69, 1986

The opiate antagonist naloxone modifies the effects of electroconvulsive shock (ECS) on respiration, blood pressure and heart rate. Brain Research 177(2): 414-417, 1979

Reduction of hypoperfusion and prevention of eeg changes in trauma plus hemorrhagic shock using a kappa opiate antagonist. Anesthesiology (Hagerstown) 73(3A): 698, 1990

The opiate antagonist naloxone modifies the effects of electro convulsive shock on respiration blood pressure and heart rate. Brain Research: 414-417, 1979